Skip to Main Content

Nektar Therapeutics Securities Fraud Class Action

View Complaint
COMPANY         Nektar Therapeutics
COURT United States District Court for the Northern District of California
CASE NUMBER 19-cv-05173
JUDGE The Hon. Jeffrey S. White
CLASS PERIOD February 28, 2019 - August 8, 2019
SECURITY TYPE  All Securities

Case Background:

On August 19, 2019, the initial complaint in this securities class action was filed against Nektar Therapeutics (“Nektar” or the “Company”), and certain of Nektar’s directors and officers, asserting violations of Sections 10(b) and 20(a) of the Securities Exchange Act. This is a federal securities class action on behalf of all other persons and entities who purchased or otherwise acquired Nektar securities between February 28, 2019 and August 8, 2019, both dates inclusive (the “Class Period”).

The complaint alleges that throughout the class period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges Defendants failed to disclose to investors that: (1) the Company did not comply with current good manufacturing practices; (2) as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (3) clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; (4) as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Current Status of Case:

On January 24, 2020, Lead Plaintiffs filed an amended complaint (the “Amended Complaint”). On January 26, 2021, the Court issued an Order granting Defendants’ Motion to Dismiss.  This action has concluded.   

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji,  Esq. (484) 270-1453; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.

Please complete this form relating to your transactions for Nektar Therapeutics (Nasdaq: NKTR) securities between February 28, 2019 and August 8, 2019, inclusive (the “Class Period”).

You may also contact Jon Naji, Esq. at (484) 270-1453; or you may submit your information via email at info@ktmc.com, or you may click here to print a PDF of this form.

SUBMIT YOUR INFORMATION
* Denotes required field
Date
# of Shares
Price per Share
Date
Principal Amount
Amount Paid
Series or CUSIP
Date
# of Contracts
Price per Contract
Exercise Price
Expiration Date
Did you purchase shares of Nektar Therapeutics (2019) prior to the Class Period?
Are you a current or former employee of Nektar Therapeutics (2019)?
The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.
I agree to the KTMC disclaimer
I would like to receive new case alerts by email